阿米万塔马布加上化学疗法在NSCLC中与EGFR外20插入
Caicun Zhou1, Ke-Jing Tang1, Byoung Chul Cho1
1From Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai (C.Z.), the Division of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Sun Yat-sen University, Guangzhou (K.-J.T.), and Harbin Medical University Cancer Hospital, Harbin (B.L.) - all in China; the Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine (B.C.C.), Asan Medical Center, University of Ulsan College of Medicine (S. Kim), and Samsung Medical Center, Sungkyunkwan University School of Medicine (K.P.) - all in Seoul, South Korea; Hospital Universitario 12 de Octubre, Madrid (L.P.-A.), and Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (E.F.) and Hospital de la Santa Creu I Sant Pau (M.M.), Barcelona - all in Spain; Sunnybrook Odette Cancer Centre, Toronto (S.C.); Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo (S. Kitazono), and Shizuoka Cancer Center, Shizuoka (A.O.) - both in Japan; General Hospital Kuala Lumpur, Kuala Lumpur, Malaysia (M.T.); David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (J.W.G.), and Janssen Research and Development, San Diego (S.M.S.) - both in California; NYU Langone Health, New York (J.K.S.); Earle A. Chiles Research Institute, Providence Cancer Institute of Oregon, Portland (R.E.S.); Mayo Clinic, Rochester, MN (A.S.M.); the Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan (J.-Y.H.); Chris O'Brien Lifehouse, Camperdown, NSW, Australia (M.B.); Royal Marsden Hospital NHS Foundation Trust and the Institute of Cancer Research, London (S.P.), and Janssen Research and Development, High Wycombe (A.B.) - both in the United Kingdom; Barretos Cancer Hospital, Barretos, Brazil (J.M.D.); Istanbul Medeniyet University, Prof. Dr. Suleyman Yalcin City Hospital, Istanbul, Turkey (M.G.); Janssen Research and Development, Raritan, NJ (J.X.); Janssen Research and Development, Spring House, PA (T.A., R.E.K.); and Institut Curie, Institut du Thorax Curie-Montsouris, Paris, and Paris Saclay University, Université de Versailles Saint-Quentin-en-Yvelines, Versailles - both in France (N.G.).
一线阿米万塔马布加化学疗法显著改善了EGFR外显子20插入的晚期非小细胞肺癌 (NSCLC) 患者的无进展生存率. 与单独的化疗相比,这种组合疗法提供了一种优越的治疗选择.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- 阿米万他马布已批准用于晚期NSCLC和EGFR外基因组20插入后的化学疗法.
- 第1阶段的数据表明,阿米万塔马布加化疗的安全性和抗瘤活性.
- 需要更多关于这种组合治疗的数据.
研究的目的:
- 评估阿米万塔马布加化学疗法与单独化学疗法作为一线治疗的疗效.
- 评估晚期NSCLC和EGFR外基子20插入患者的无进展生存期.
主要方法:
- 第三阶段,国际,随机试验与1:1分配.
- 患者接受了amivantamab化疗或单独的化疗.
- 主要结局:通过盲目的独立中央审查无进展生存.
主要成果:
- 艾米万他马布化学疗法显著延长了无进展的生存时间 (11.4个月与6.7个月相比;P<0.001).
- 对象性反应率在阿米万他马布化学疗法中较高 (73%对47%;P<0.001).
- 副作用是可以管理的,主要是可逆的血液和EGFR相关毒性.
结论:
- 与单独的化疗相比,amivantamab-化疗在一线治疗中显示出更高的疗效.
- 这种组合是一个有前途的新标准的护理高级NSCLC与EGFR外基子20插入.
相关概念视频
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...


